Table S2.
The adjusted HRs with 95% CIs of drug discontinuation followed by antibiotics prescription for adalimumab compared with etanercept on concomitant MTX >10 mg/wk during all treatment periods, ≤1 year or >1 year, stratified by other covariates with the significance of their modification effects
| Variable | All treatment period (n=1,731)
|
Within 1 year (n=2,056)
|
After 1 year (n=606)
|
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P for modification | HR (95% CI) | P for modification | HR (95% CI) | P for modification | |
| Age | 0.851 | 0.100 | 0.246 | |||
| <65 years | 1.48 (1.12–1.97) | 1.76 (1.20–2.59) | 1.12 (0.62–2.02) | |||
| ≥65 years | 1.72 (1.07–2.75) | 3.57 (1.80–7.06) | 3.44 (0.87–13.56) | |||
| Sex | 0.733 | 0.610 | 0.502 | |||
| Female | 1.51 (1.15–1.98) | 2.03 (1.40–2.95) | 1.20 (0.68–2.12) | |||
| Male | 1.76 (1.04–2.99) | 2.62 (1.27–5.42) | 1.90 (0.53–6.87) | |||
| Disease duration | 0.291 | 0.465 | 0.205 | |||
| <3 years | 1.91 (1.17–3.14) | 2.45 (1.23–4.87) | 3.38 (0.89–12.82) | |||
| ≥3 years | 1.47 (1.11–1.94) | 2.05 (1.40–2.99) | 1.16 (0.64–2.10) | |||
| History within 1 year before anti-TNF treatment | ||||||
| CCI | 0.562 | 0.908 | 0.074 | |||
| <2 | 1.40 (0.98–1.98) | 2.16 (1.37–3.41) | 0.83 (0.38–1.84) | |||
| ≥2 | 1.69 (1.20–2.37) | 2.29 (1.41–3.73) | 2.31 (1.11–4.82) | |||
| MTX, mg/wk | 0.841 | 0.180 | 0.304 | |||
| ≤10 | 1.42 (0.90–2.23) | 3.15 (1.63–6.11) | 0.92 (0.33–2.57) | |||
| >10 | 1.50 (1.13–2.00) | 1.86 (1.26–2.73) | 1.57 (0.84–2.91) | |||
| SSZ | 0.026 | 0.643 | 0.771 | |||
| No | 2.47 (1.49–4.08) | 2.62 (1.34–5.12) | 1.82 (0.58–5.76) | |||
| Yes | 1.31 (0.99–1.74) | 1.93 (1.31–2.84) | 1.27 (0.70–2.29) | |||
| LEF | 0.945 | 0.668 | 0.597 | |||
| No | 1.52 (1.14–2.03) | 2.17 (1.48–3.19) | 1.16 (0.60–2.24) | |||
| Yes | 1.50 (0.95–2.38) | 2.00 (1.03–3.86) | 1.97 (0.80–4.83) | |||
| HCQ | 0.106 | 0.587 | 0.745 | |||
| No | 2.83 (1.42–5.62) | 3.35 (1.24–9.10) | 1.14 (0.28–4.62) | |||
| Yes | 1.40 (1.08–1.82) | 2.02 (1.42–2.87) | 1.24 (0.70–2.18) | |||
| NSAID | 0.846 | 0.893 | 1.00 | |||
| No | a | a | b | |||
| Yes | 1.50 (1.18–1.91) | 2.10 (1.51–2.92) | 1.32 (0.80–2.23) | |||
| Pd equivalent | 0.004 | 0.244 | 0.020 | |||
| ≤5 mg/d | 1.33 (0.86–2.05) | 1.87 (1.07–3.29) | 0.31 (0.09–1.08) | |||
| >5 mg/d | 1.64 (1.22–2.20) | 2.25 (1.49–3.40) | 2.31 (1.24–4.26) | |||
| Comedication | ||||||
| SSZ | 0.182 | 0.975 | 0.108 | |||
| No | 1.82 (1.27–2.61) | 2.08 (1.30–3.32) | 0.98 (0.53–1.84) | |||
| Yes | 1.38 (0.99–1.92) | 2.21 (1.38–3.54) | 2.22 (0.75–6.62) | |||
| LEF | 0.794 | 0.251 | 0.271 | |||
| No | 1.51 (1.16–1.96) | 1.97 (1.39–2.80) | 1.36 (0.80–2.34) | |||
| Yes | 1.53 (0.81–2.86) | 3.28 (1.06–10.15) | 1 | |||
| HCQ | 0.921 | 0.434 | 0.655 | |||
| No | 1.61 (1.04–2.48) | 1.92 (1.07–3.44) | 1.49 (0.73–1.24) | |||
| Yes | 1.50 (1.12–2.00) | 2.20 (1.48–3.29) | 1.29 (0.58–2.84) | |||
| NSAID | 0.960 | 0.968 | 0.888 | |||
| No | a | a | a | |||
| Yes | 1.51 (1.19–1.93) | 2.12 (1.52–2.96) | 1.28 (0.75–2.18) | |||
| Pd equivalent | 0.879 | 0.594 | 0.868 | |||
| ≤5 mg/d | 1.59 (1.15–2.21) | 2.33 (1.48–3.66) | 1.36 (0.73–2.54) | |||
| >5 mg/d | 1.43 (1.00–2.05) | 1.86 (1.14–3.03) | 1.82 (0.62–5.32) | |||
Notes: Cox proportional hazard regression analyses were conducted to calculate adjusted HRs after adjusting for sex, age at anti-TNF initiation (≤65 years, >65 years), disease duration (≤3 years, >3 years), CCI (≤1, >2) within 1 year before anti-TNF use, use of LEF, SSZ, NSAID, MTX (0–10 mg/wk, >10 mg/wk), and corticosteroid (Pd equivalent ≤5 mg/d, >5 mg/d) within 1 year before and after anti-TNF use.
95% CI was very large and covered one (ie, nonsignificant).
All patients used NSAID before anti-TNF initiation.
Abbreviations: HRs, hazard ratios; CI, confidence intervals; MTX, methotrexate; TNF, tumor necrosis factor; CCl, Charlson comorbidity index; SSZ, salazopyrin; LEF, leflunomide; HCQ, hydroxychloroquine; NSAID, nonsteroid anti-inflammatory drug; Pd, prednisolone.